Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Statins Linked to Idiopathic Inflammatory Myositis

Will Boggs, MD  |  July 31, 2018

NEW YORK (Reuters Health)—Statin use is associated with an increased likelihood of developing idiopathic inflammatory myositis (IIM), researchers from Australia report.

“[Although] the incidence of IIM is rare, with the increasing use of statins worldwide and the severity of this condition, this study highlights the need for increased awareness of the condition and the importance of early recognition and treatment,” Dr. Gillian E. Caughey from Adelaide Medical School and the University of Adelaide tells Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

IIM is a group of rare autoimmune muscular disorders that can result in permanent disability and death. A statin-associated autoimmune myopathy appears to result from a specific autoantibody against HMG-CoA reductase. Its incidence is unknown.

Dr. Caughey’s team used data from the South Australian Myositis Database and North West Adelaide Health Study to examine the association between current exposure to statins and histologically confirmed IIM.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Statin exposure was significantly more common among IIM cases (30.8%) than among matched controls (21.5%), according to the July 30 JAMA Internal Medicine online report.1

After adjustment for other factors, including the higher prevalence of diabetes and lower prevalence of cardiovascular disease among cases, there was a 79% increased likelihood of statin exposure in patients with IIM in comparison with controls.

Half of the patients with necrotizing myositis were exposed to a statin, compared with 30.3% of those with polymyositis or inclusion body myositis and only 17.4% of those with dermatomyositis.

After excluding cases of necrotizing myositis from the analysis, statin exposure was 89% more likely in cases than in controls.

The proportion of patients with IIM exposed to statins increased from 5.6% in 2000–2002 to 48.8% in 2012–2014.

“We do not want the results of this study to undermine the benefits of statin use for reduction of primary and secondary cardiovascular risk,” Dr. Caughey says. “Statins are generally well tolerated by patients. Myalgia and myopathy are relatively common adverse effects associated with statin use; IIM is a rare condition and statin-induced IIM is even rarer. However, consideration of the potential risk of IIM in the assessment of net risks and benefits of statin use and early recognition of the disease will help to improve health outcomes for patients.”

“This study assessed statin exposure by different methods for cases (drug history in the medical record) and controls (prescription dispensing records), which may have resulted in misclassification bias,” writes Dr. Gregory Curfman, JAMA Internal Medicine Health Care Policy and Law editor from Brigham and Women’s Hospital and Harvard Medical School, Boston, in an editorial. “Thus, the association of IIM with statin therapy … cannot be considered definitive, although these are likely the best data currently available.”2

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsMyositis Tagged with:idiopathic inflammatory myositismyositisStatinstatin-associated myopathy

Related Articles

    Drug Updates

    January 1, 2009

    Information on safety, labeling changes, and pharmaceutical research

    Myositis Mysteries

    January 1, 2008

    Why isn’t my myositis patient getting better?

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences